Still, Mahaffey et al. discussed the use of SGLT2 inhibitors for primary prevention of cardiac disorders vs. secondary preventions of complications in patients with existing cardiac abnormalities in T2DM patients [23]. Here, SLC5A2 is linked to type 2 diabetes mellitus.